Brought to you by 
Cadila forms JV with Novavax to develop vaccines in India
05 Dec 2022
Executive Summary
Indian pharma company Cadila Pharmaceuticals and Novavax (vaccines for infectious diseases) have formed CPL Biologicals Ltd., a joint venture to develop and market Novavax's seasonal influenza virus-like-particle-based (VLP) vaccine drug candidate and Cadila's cancer vaccines, adjuvants, biogeneric products, and diagnostics in India.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
- Liposomes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cadila forms JV with Novavax to develop vaccines in India
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice